High grade start to 2016 for CZL

|

Published 02-FEB-2016 15:45 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Consolidated Zinc Ltd (ASX:CZL) has begun the year with an outstanding first phase drilling result” in excess of 27% zinc (Zn) and 60.4g/t gold (Ag) at its flagship Plomosas mine in Mexico.

Having resumed exploration work as quickly as possible following the Christmas break, CZL says its “drilling has successfully improved the understanding of the geological setting, structure and mineralisation prior to a drill out of the area and resource modelling.”

CZL hopes to obtain its Maiden JORC resource sometime later this year after completing a Scoping Study as a priority.

CZL is currently focused on its flagship Plomosas Zinc Project in Mexico, covering 11 exploration concessions spanning over 3000 hectares in the northern Mexican state of Chihuahua. Over 2 million tonnes of ore have been mined at Plomosas in the past, with an average zinc + lead grade of 22% and over 80g/t Ag. CZL currently has a 51% stake in the project, but is aiming to increase this to above 80% subject to milestones being met.

Since the start of this year, CZL has drilled three drill holes for a total of 490m with a fourth currently in progress. Detailed assay results for all four are imminent although preliminary results have already been received for one.

The LV7DD002 hole returned 6.75m @ 27.2% Zn, 12.7% Pb and 60.4 g/t Ag from 45.25m.

CZL says that detailed assay results are still pending, but preliminary results already indicate high grade zinc mineralisation with LV7DD002 intersecting a 6.75m sequence comprising 4.5m of “massive zinc sulphide mineralisation over 2.25m unit of collapse breccia mineralisation”.

CZL’s Managing Director Will Dix said, “This is an outstanding result for the first phase of drilling...and a great start for 2016. It’s exciting to see our geological model validated with such encouraging results.”

CZL Managing Director, Will Dix

Exploration drilling and further geological analysis remains a top priority for CZL. The company says that “drilling will continue both in the main zone extensions and at Tres Amigos where we [CZL] are working hard towards our maiden resource estimate.”

tags

ZINC


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X